Division of Gastroenterology, Department of Internal Medicine, University of Debrecen, Debrecen, Hungary.
Institute of Surgery, University of Debrecen, Debrecen, Hungary.
Liver Int. 2016 Nov;36(11):1628-1638. doi: 10.1111/liv.13133. Epub 2016 May 5.
BACKGROUND & AIMS: Innate immune system dysfunction is common in advanced cirrhosis, with a central role of the monocyte/macrophage system. Monocytes and macrophages express the scavenger receptor CD163, which is regulated by inflammatory mediators. Cleavage of the receptor leads to the formation of soluble (s)CD163 that represents an anti-inflammatory response. We aimed to study the clinical importance of sCD163 in cirrhosis.
Sera of 378 patients were assayed for sCD163 by ELISA [193 outpatients and 185 patients with acute decompensation (AD)]. A 5-year follow-up observational study was conducted to assess the possible association between sCD163 level and poor disease outcomes.
sCD163 level was associated with disease severity, but not with the presence of varices or prior variceal bleeding. In outpatients, sCD163 level did not predict the development of disease-specific complications or the long-term mortality. In patients with AD episode, sCD163 level was significantly higher compared to outpatients but only in the presence of bacterial infection (INF) (AD-INF:4586, AD-NON-INF:3792 and outpatients: 3538 ng/ml, P < 0.015 and P = 0.001, respectively). sCD163 level gradually increased according to severity of infection. During bacterial infections, high sCD163 level (>7000 ng/ml) was associated with increased mortality rate (42% vs. 17%, P < 0.001) and was identified as an independent predictor of 28-day mortality (hazard ratio:2.96, 95% confidence intervals:1.27-6.95) in multivariate Cox-regression model comprising aetiology, co-morbidity, model for end-stage liver disease score and leucocyte count as covariates.
High sCD163 level is useful to identify patients with high-risk of death during an AD episode complicated by bacterial infection. This finding serves as an additional hint towards the significance of anti-inflammatory response during bacterial infection.
先天免疫系统功能障碍在晚期肝硬化中很常见,其中心环节为单核细胞/巨噬细胞系统。单核细胞和巨噬细胞表达清道夫受体 CD163,该受体受炎症介质调节。受体的裂解导致形成可溶性 (s)CD163,这代表一种抗炎反应。我们旨在研究肝硬化中 sCD163 的临床重要性。
通过 ELISA 检测 378 例患者的血清 sCD163[193 例门诊患者和 185 例急性失代偿 (AD) 患者]。进行了一项为期 5 年的观察性研究,以评估 sCD163 水平与不良疾病结局之间的可能关联。
sCD163 水平与疾病严重程度相关,但与静脉曲张的存在或既往静脉曲张出血无关。在门诊患者中,sCD163 水平不能预测疾病特异性并发症或长期死亡率。在 AD 发作患者中,sCD163 水平明显高于门诊患者,但仅在存在细菌感染 (INF) 时 (AD-INF:4586,AD-NON-INF:3792 和门诊患者:3538ng/ml,P<0.015 和 P=0.001)。sCD163 水平根据感染严重程度逐渐升高。在细菌感染期间,高 sCD163 水平 (>7000ng/ml) 与死亡率增加相关 (42% vs. 17%,P<0.001),并在包含病因、合并症、终末期肝病模型评分和白细胞计数作为协变量的多变量 Cox 回归模型中被确定为 28 天死亡率的独立预测因子 (危险比:2.96,95%置信区间:1.27-6.95)。
高 sCD163 水平可用于识别 AD 发作合并细菌感染时死亡风险高的患者。这一发现为细菌感染期间抗炎反应的重要性提供了额外的提示。